Q-omics provides the consensus-scored SNORA63D profile across patient tissues and cancer cell-line models. SNORA63D expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, SNORA63D is differentially expressed in 3, with the highest sampling consensus in LUAD. Additionally, SNORA63D RNA expression shows 11,492 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight KICH, LUAD, and HNSC as cancer lineages where SNORA63D shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORA63D — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORA63D survival associations across molecular data types. SNORA63D RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORA63D RNA expression–survival associations across cancer types. High SNORA63D expression shows unfavorable associations in KICH, THYM, MESO, UCEC and READ, but favorable associations in BLCA. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for SNORA63D RNA expression.
This table summarizes SNORA63D tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for SNORA63D. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORA63D shows higher tumor expression in LUAD, COAD and LUSC. The LUAD box plot shows higher SNORA63D RNA expression in tumor versus normal tissue (log2 FC = +0.482, t-test p = .011).
This table shows molecular features associated with SNORA63D in patient tissues and cancer cell lines. In patient samples, SNORA63D shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set.
